IRVINE, Calif., May 7, 2024 /PRNewswire/ -- Seragon Biosciences,
Inc. today announced the completion of a pre-clinical study on its
novel anti-aging candidate, SRN-901. This pivotal study, conducted
in mice, was undertaken to evaluate the impact of SRN-901 on aging
as well as various health markers.
Results from the study show that SRN-901 achieved one of the
largest extensions of lifespan and healthspan to date in the
treated population. Whole-genome transcriptome sequencing was
performed on over 300 mice to assess the effects of SRN-901 at a
molecular level. The results highlighted a significant increase in
the expression of many genes associated with longevity and a
notable reduction in the expression of genes linked to aging.
Additionally, a metabolic panel revealed beneficial changes in
several biomarkers associated with younger biological age.
Other tests were conducted to evaluate the effect of SRN-901 on
healthspan, a measure of how long health is maintained over the
course of one's life. The study also evaluated physical and
cognitive function. Treadmill tests showed significantly enhanced
endurance in elderly mice. Frailty scores showed marked improvement
in the elderly mice receiving SRN-901, and there was a significant
reduction in tumor occurrence in the treated group.
The research team at Seragon Biosciences is encouraged by the
study's results and will conduct further analysis to uncover
additional findings. These results will be published once the
supplementary analysis is complete.
About Seragon Biosciences
Seragon Biosciences, Inc., headquartered in Irvine, California, is a research-based
biopharmaceutical company dedicated to improving human and animal
health through innovative science. Seragon Biosciences is
committed to applying cutting-edge scientific and technological
advancements to the fields of aging, metabolism, gene therapy, and
bioinformatics. From the research end to consumer products and
clinical applications, Seragon strives to bring people access to
the most significant breakthroughs in medicine. For more
information, please visit www.seragon.com.
Logo -
https://mma.prnewswire.com/media/1986399/Seragon_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/seragon-completes-pre-clinical-study-of-aging-intervention-candidate-srn-901-302137592.html